Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA

Phathom Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.73

Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.
Cash $248.8M at June 30; $100M available from Hercules on Oct 1, $175M upon Erosive GERD approval.
FDA PDUFA dates: Oct 30 for VOQUEZNA H. pylori packs; Nov 17 for Erosive GERD NDA.
Completed public offering May 2023 with $141.4M net proceeds.
Phase 3 PHALCON-NERD-301 completed; regulatory submission for Non-Erosive GERD on track H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phathom Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income $41.0 million.

Period: the quarter ended June 30, 2023
Net income: $41.0 million
Result: reported results

Exact text from the filing

Net loss for the second quarter ended June 30, 2023, was $41.0 million, compared to $50.9 million for second quarter 2022.

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.